CoChat

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 3 of the 30 sources its claims cite were checked for support.

Abstract

PURPOSE: To investigate the efficacy and safety of dienogest as a long-term treatment in endometriosis, with follow-up after treatment discontinuation. The study included women with endometriosis, who had previously completed a 12-week, placebo-controlled study of dienogest, who participated in an open-label extension study for up to 53 weeks. Thereafter, a patient subgroup was evaluated in a 24-week follow-up after treatment discontinuation. METHODS: A multicenter study performed in Germany, Italy and Ukraine. Women with endometriosis were enrolled at completion of the placebo-controlled study (n = 168). All women received dienogest (2 mg once daily, orally) and changes in pelvic pain (on a visual analog scale), bleeding pattern, adverse events and laboratory parameters were evaluated during and after treatment. RESULTS: The completion rate among women who entered the open-label extension study was 90.5% (n = 152). A significant decrease in pelvic pain was shown during continued dienogest treatment (P < 0.001). The mean frequency and intensity of bleeding progressively decreased. Adverse events, rated generally mild or moderate, led to withdrawal in four patients (2.4%). No clinically relevant changes in laboratory parameters were observed. During treatment-free follow-up (n = 34), the reduction in pelvic pain persisted, while bleeding frequency and intensity returned to normal patterns. CONCLUSIONS: Long-term dienogest showed a favorable efficacy and safety profile, with progressive decreases in pain and bleeding irregularities during continued treatment; the decrease of pelvic pain persisted for at least 24 weeks after treatment cessation.

Overview

CoChat Summary

TL;DR

In women with endometriosis who completed a prior 12-week placebo-controlled dienogest trial, continued open-label dienogest 2 mg/day for up to 53 weeks significantly reduced endometriosis-associated pelvic pain, with the reduction persisting during 24 weeks of treatment-free follow-up. Long-term dienogest also progressively reduced bleeding frequency/intensity and showed a generally mild-to-moderate adverse-event profile.

Key findings

  • Among 168 women entering the extension study, 152 (90.5%) completed planned treatment; mean VAS for pelvic pain decreased from 34.08 ± 21.60 mm at extension baseline to 11.52 ± 11.26 mm at end of treatment, with a mean reduction of 43.2 ± 21.7 mm over the total 65-week treatment period (P < 0.001).
  • During treatment-free follow-up (n = 34), pain reduction largely persisted: mean VAS was 16.29 ± 14.08 mm at week 12 and 14.56 ± 9.55 mm at week 24.
  • Bleeding pattern improved during continued treatment: women with “no bleeding” in 90-day reference periods increased from 5.5% to 23.5%, while “heavy bleeding” decreased from 9.8% to 2.2%; bleeding returned to normal cyclic patterns within 4–6 weeks after treatment cessation.
  • Treatment-related adverse events occurred in 27/168 women (16.1%), most commonly breast discomfort (4.2%), nausea (3.0%), and irritability (2.4%); adverse events led to withdrawal in 4 patients (2.4%), and 3 women (1.8%) had serious adverse events.

Methods

  • Open-label, single-arm extension study at 28 centers in Germany, Italy, and Ukraine; 168 women with laparoscopically confirmed endometriosis who had completed a 12-week randomized, double-blind, placebo-controlled dienogest study received dienogest 2 mg once daily orally for up to 53 weeks (total treatment up to 65 weeks).
  • A subgroup of 34 women at six centers entered a 24-week treatment-free follow-up after the extension study.
  • Main assessments included endometriosis-associated pelvic pain by 100-mm VAS every 4 weeks, uterine bleeding pattern over 90-day reference periods, adverse events, laboratory parameters, vital signs, body weight, and SF-36 quality of life; analyses used the full analysis set and were primarily descriptive, with a one-sample t test for change in VAS from randomization to end of extension.

Limitations

  • The authors state potential weaknesses: the open-label design and recruitment of patients who had participated in an earlier placebo-controlled study, including a proportion who responded favorably to prior dienogest therapy.
  • The extension study was single-arm with no concurrent placebo or active comparator, so long-term efficacy is not compared against another treatment.
  • The treatment-free follow-up was limited to a small subgroup (n = 34) at six centers, and efficacy/safety analyses were primarily descriptive; the protocol treatment duration was also changed from 36 to 52 weeks, with 26 patients completing before this prolongation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00404-011-1941-7

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Patient disposition during the extension study and the treatment-free follow-up period
Fig. 1 Patient disposition during the extension study and the treatment-free follow-up periodCC BY-NC · PubMed Central
Fig. 2 Mean (±SEM) VAS scores for EAPP during the extension study (FAS) in the total, prior-dienogest and prior-placebo groups. Mean VAS score was statistically significantly reduced by 43.2 (±21.7) mm over the total treatment period of 65 weeks (i.e., placebo-controlled plus extension study; P < 0.001). EAPP endometriosis-associated pain, FAS full analysis set, SEM standard error of the mean, VAS visual analog scale
Fig. 2 Mean (±SEM) VAS scores for EAPP during the extension study (FAS) in the total, prior-dienogest and prior-placebo groups. Mean VAS score was statistically significantly reduced by 43.2 (±21.7) mm over the total treatment period of 65 weeks (i.e., placebo-controlled plus extension study; P < 0.001). EAPP endometriosis-associated pain, FAS full analysis set, SEM standard error of the mean, VAS visual analog scaleCC BY-NC · PubMed Central
Fig. 3 Frequencies of maximal intensity of bleeding in 90-day reference periods 1 and 4 during dienogest treatment in the extension study (FAS) FAS full analysis set
Fig. 3 Frequencies of maximal intensity of bleeding in 90-day reference periods 1 and 4 during dienogest treatment in the extension study (FAS) FAS full analysis setCC BY-NC · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 17 Not checked · 37 Own results and interpretations

19 more claims

Create a free account to see all 57 claims and to verify the 27 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 24 references

Cited by

See all 213

Metadata

Authors
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T.
Affiliations
  • University of Siena (IT)
  • University of Lübeck (DE)
  • Bayer (Germany) (DE)
  • Heidelberg University (DE)
Corresponding author
Petraglia, Felice
Venue
Archives of Gynecology and Obstetrics
Published
2011-06-17
Volume
285
Issue
1
Pages
167-173
ISSN
  • 0003-9128 (ISSN-L)
  • 0932-0067
  • 1432-0711
OpenAlex
W2159474777
Cited by
200
References
23
Citations by year
2026: 9 · 2025: 10 · 2024: 11 · 2023: 7 · 2022: 12 · 2021: 18 · 2020: 8 · 2019: 6 · 2018: 18 · 2017: 25 · 2016: 14 · 2015: 21 · 2014: 18 · 2013: 10 · 2012: 8
FWCI
14.70
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Archives of Gynecology and Obstetrics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
Funders
Bayer HealthCare
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
Keywords
endometriosis, dienogest, long-term treatment, pelvic pain, dysmenorrhea, bleeding patterns, treatment discontinuation, open-label extension, adverse events, treatment efficacy and safety
MeSH terms
Adolescent, Adult, Drug Administration Schedule, Endometriosis, Female, Follow-Up Studies, Germany, Hormone Antagonists, Humans, Italy, Middle Aged, Nandrolone, Ukraine, Pelvic Pain, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. https://app.cochat.ai/papers/10.1007/s00404-011-1941-7
The paper
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012). Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-011-1941-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.